We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Low Cost Biosensor to Be Based on Printing Technologies

By LabMedica International staff writers
Posted on 14 Sep 2011
Scientists intend to use the latest printing technologies to develop a low cost biosensor capable of diagnosing a range of health conditions.

Living antibodies will be placed into a suitable ink and then printed onto a compatible substrate or material to form a disposable sensor, capable of being mass-produced at low cost. More...
The printed array of antibodies speeds up the testing process while reducing the expertise and complexity of equipment needed--introducing the possibility of hand held electronic scanners and far quicker diagnosis.

Antibody based assays are routinely used to detect specific medical conditions but use of these tests is limited because they need to be carried out in laboratories by highly skilled technicians, which is costly and time consuming.

The team developing the new technique is led by Prof. Tim Claypole, head of Swansea University's Welsh Center of Printing and Coating (Wales, United Kingdom). Prof. Claypole said the project is at the forefront of international research and represents a major advance in the printing of biomedical sensors.

“The availability of low cost, disposable sensor technology is a core requirement for the early diagnosis of disease. The use of antibodies as sensors targeted to detect specific human conditions is regarded as one of the next major advances in health care.

“Volume printing is also the most practical method to achieve low cost disposable sensor technology. This will take innovation from the bench to the bedside and develop the tools and technologies to move the process of diagnosis forward and bring it into the surgery and home.”

In addition to allowing some aspects of patient care to be moved from the hospital or laboratory to the GP surgery, the new biosensor technology could also be useful in emergency situations and in remote areas.

The project is supported by the Welsh Government's Academic Expertise for Business (A4B), an EU funded initiative to stimulate and encourage collaboration between educational institutions and industry.

The initial focus will be developing a proof of concept device that will open opportunities to develop antibody sensors to diagnose a broad range of health conditions.

Related Links:

Swansea University's Welsh Center of Printing and Coating
Welsh Government's Academic Expertise for Business




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
All-in-One Molecular System
AIO M160
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.